Diabetes

Evansville, IN

131 Diabetes Trials near Evansville, IN

Power is an online platform that helps thousands of Diabetes patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Screening Program for Chronic Kidney Disease in Type 2 Diabetes

Nashville, Tennessee
IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

800 Participants Needed

Lanifibranor for Nonalcoholic Steatohepatitis (NASH)

Nashville, Tennessee
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1000 Participants Needed

Glucose Metabolism Tracer for Metabolism

Nashville, Tennessee
The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

12 Participants Needed

Renal Denervation for High Blood Pressure

Nashville, Tennessee
This trial is studying the safety and effectiveness of a device called the Symplicity Spyral system, which helps lower blood pressure by calming overactive nerves in the kidneys. It includes patients who have already received this treatment. The Symplicity Spyral system is part of a series of treatments, with earlier versions showing significant blood pressure reductions in patients with resistant hypertension.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

1400 Participants Needed

LY3841136 + Tirzepatide for Obesity with Type 2 Diabetes

Nashville, Tennessee
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

350 Participants Needed

Naronapride for Gastroparesis

Nashville, Tennessee
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

320 Participants Needed

Empagliflozin for Kidney Transplant Recipients

Nashville, Tennessee
Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging. Patient death with existing kidney graft function occurs in about half of all recipients over time. This is primarily due to the development of cardiovascular disease in a patient population with multiple preexisting cardiac disease risk factors. There has been little progress in improving outcomes in this area for over two decades. Recent studies in chronic kidney disease (CKD) patients using SGLT2 inhibitors (SGLT2i), regardless of the presence of type 2 diabetes mellitus (T2DM), results in both kidney protective and cardiac protective impacts and improved patient outcomes. However, kidney transplant recipients (KTRs) were excluded from these clinical trials due to concerns that these agents promote infection, diminish graft function, and may alter immunosuppressive drug levels that are the mainstay of patient's transplant therapy. There are limited published data of SGLT2i treatment of selected KTRs.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:19+

264 Participants Needed

Tirzepatide for Obesity and Chronic Kidney Disease

Avon, Indiana
This trial is testing tirzepatide to see if it can help people with obesity, with or without type 2 diabetes, who have chronic kidney disease. The medication works by controlling blood sugar and reducing weight, which may improve kidney function. Tirzepatide is a new medication given regularly, effective in treating obesity in patients with and without diabetes.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

140 Participants Needed

Siplizumab for Type 1 Diabetes

Indianapolis, Indiana
This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0. Participants will be randomized 1:1:1:1 to one of four possible siplizumab dosing arms. All dosing arms will receive weekly siplizumab doses for a total of 12 weeks. After the completion of treatment, participants will undergo follow-up visits at weeks 12, 24, 36 and 52 which include longitudinal MMTTs. If indicated, participants will enter into long-term safety monitoring for up to an additional 48 weeks. Blood samples for mechanistic analyses will be obtained during the treatment phase and thereafter. Adults aged 18- 45 will be enrolled initially at the study sites. The primary objective is to identify a safe, metabolically favorable, dosing regimen for siplizumab in patients with type 1 diabetes that induces changes in T cell phenotypes observed with alefacept therapy in new-onset T1DM. The secondary objectives are to: 1. Assess the safety profile of siplizumab in recently diagnosed T1DM. 2. Assess the effects of siplizumab on residual beta cell function in recently diagnosed T1DM participants.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:8 - 45

120 Participants Needed

Continuous Glucose Monitoring for Diabetes

Indianapolis, Indiana
The purpose of this study is to find out how well a new continuous glucose monitor works for people with diabetes. This study will test the performance of the study sensor(s) for 7-14 days of wear in patients who are 11-80 years old with type 1 or type 2 diabetes.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:11 - 80

1500 Participants Needed

RYBELSUS® for Type 2 Diabetes

Gillespie, Illinois
This trial is testing RYBELSUS®, a tablet that lowers blood sugar, in people with type 2 diabetes who need extra treatment. The study will compare RYBELSUS® to other similar tablets over several months. Participants will have regular doctor visits and complete some questionnaires. Pregnant or breastfeeding women cannot join. RYBELSUS® is an oral form of a medication that has been used in injectable form for managing type 2 diabetes.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4

1262 Participants Needed

Denosumab for Type 1 Diabetes

Indianapolis, Indiana
Type 1 diabetes (T1D) arises from abnormal immune cell-mediated injury to beta cells that make insulin. The injured beta cells can then no longer make the needed amount of insulin to stay healthy. However, in the early stages of T1D, some beta cells are still alive and functioning. Treatment to protect the beta cells against injury at this time could slow the progress of disease. Denosumab is an approved treatment for osteoporosis (a disease that thins and weakens the bones), high blood calcium levels, bone cancer, and other bone problems in patients who have cancer. The research team has found that the bone pathway that denosumab works on to treat these bone conditions also has effects on the health of the beta cells. Lab studies suggest that denosumab may protect and/or increase the number of beta cells and improve how well they work. This study will test whether denosumab is safe and improves beta cell function and blood sugar control in people with early T1D.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 50

45 Participants Needed

DFMO for Type 1 Diabetes

Indianapolis, Indiana
The goal of this clinical trial is to test a drug known as DFMO in people with Type 1 Diabetes (T1D). The main question\[s\] it aims to answer are: * Does it reduce stress on the cells that make insulin? * Does it preserve what is left of the body's insulin production? Participants will take either DFMO or a placebo (looks like DFMO but has no active ingredients) two times a day for about 6 months. Participants will have 6 in person visits and 1 phone visit over a period of 12 months. Visits will include blood draws urine collection and other tests.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:4 - 40

70 Participants Needed

Metformin for Type 1 Diabetes and Obesity

Indianapolis, Indiana
Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweight and obesity as well as potential mechanisms to modify disease.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:11 - 18

114 Participants Needed

LY3457263 for Type 2 Diabetes

Brownsburg, Indiana
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

240 Participants Needed

R-5280 (HAMS-AB) for Type 1 Diabetes

Indianapolis, Indiana
Evaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:11 - 17

39 Participants Needed

Hybrid Closed Loop System for Type 1 Diabetes

Indianapolis, Indiana
The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A diverse population of patients with type 1 diabetes will be studied. The study population will have a large range for duration of diabetes and glycemic control, as measured by glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior diabetes regimen, including using Multiple Daily Injections (MDI), Continuous Subcutaneous Insulin Infusion (CSII) or Sensor-Augmented Pump therapy (SAP)
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:2 - 80

280 Participants Needed

Mind-Body Skills Training for Type 1 Diabetes

Indianapolis, Indiana
Adolescence presents a challenging time for type 1 diabetes management, and despite a multitude of studies aimed at increasing disease compliance in this age group, none have been deemed superior. The purpose of this study is to incorporate mindfulness skills in with diabetes education sessions for adolescents with type 1 diabetes and study if this translates to improved outcomes in glycemic control, patient satisfaction, and mental wellness.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:15 - 17

30 Participants Needed

Sensing Device for Diabetes

Indianapolis, Indiana
The purpose of this study is to determine whether an array of biosensors can noninvasively identify hyperglycemic or hypoglycemic events in persons diagnosed with diabetes through noninvasive detection of volatile organic compounds in exhaled breath.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:12 - 19

20 Participants Needed

Percutaneous Electrical Nerve Field Stimulation for Gastroparesis

Indianapolis, Indiana
The purpose of this study is to find out if we can stimulate the vagus nerve. The vagus nerve is a largely internal nerve that controls many bodily functions, including stomach function. We hope that electrically stimulating the nerve around the external ear will also stimulate the internal vagus nerve. If it does, then we hope that this will help our treatment of patients with nausea and vomiting and disordered stomach function.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18 - 60

60 Participants Needed

Why Other Patients Applied

"Years ago, Metformin didn't help. I'm currently on Rybelsus & Farxiga. Not doing me much good. My insurance won't cover any of the injectables. Excited to try something new."

QL
Diabetes PatientAge: 71

"Looking for better ways to manage my diabetes, high blood pressure and overall health. Hoping to improve my health all together in order to have a better life & to enjoy my children & grandchildren."

OK
Diabetes PatientAge: 66

"I have already lost part of a leg to an infection. I want to try to get this horrific condition under control and get back to my life. It's taken enough."

WY
Diabetes PatientAge: 40

"I have had type 2 diabetes for some time now and would love to be part of a study... should the study drug work out as a successful treatment, then I would be glad to be one of the first patients in line!"

MB
Diabetes PatientAge: 67

"I've been in pain for years. It's been crippling and has massively impacted my life. I want to be free. Diabetes changed everything at 15. Diabetic Type 1 for 20 years. SEVERE Peripheral Neuropathy onset 7-8 years in. Have been living with it since. Have tried every drug, everything. Gaba, lyrica, all opioids, electrical current therapy, massages, acupuncture, cupping, everything. Currently taking low dose of duloxetine, have an insulin pump but its not good enough. Want to try a cutting-edge med."

YN
Diabetes PatientAge: 35

Lifestyle Interventions for Gestational Diabetes

Indianapolis, Indiana
The goal of this study is assess the impact of a higher intensity dietary and activity counseling program to improve blood sugar control and reduce the chance of developing gestational diabetes (GDM) as compared to the current standard diet and activity counseling.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:14+
Sex:Female

100 Participants Needed

Electronic Diabetes Tune-Up for Type 2 Diabetes

Indianapolis, Indiana
The primary aims of this study are: 1. To test the acceptability and feasibility of the electronic DTU intervention (eDTU) that has been adapted for cultural relevance and online delivery compared to waitlist control and the in-person DTU (iDTU). The hypothesis is that the adapted intervention will be culturally acceptable (by participant satisfaction scores) and well-subscribed (intervention attendance rates). 2. To test differences in diabetes distress and A1c change scores between intervention (changes in T2 to T4) and waitlist control (change in T1 to T2) by intervention group (eDTU vs. waitlist control; iDTU vs. waitlist control). The hypothesis is that both the eDTU and iDTU groups will show significant improvements in diabetes distress and A1c compared to waitlist control. In order to conserve sample size and budget, participants in each intervention group will serve as their own waitlist control. Secondary Objective. The secondary aim of the study is to evaluate changes in depressive symptoms, diabetes self-efficacy, and general and diabetes-specific quality of life in intervention (T2-T3 \& T4) compared to waitlist control (T1-T2). An exploratory aim will be to compare changes in eDTU to the iDTU pre/post intervention (T2-T3 \& T4). The hypothesis is that both groups will show comparable improvements in diabetes distress and A1c.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:21+
Sex:Female

60 Participants Needed

Retatrutide for Chronic Kidney Disease and Obesity

Indianapolis, Indiana
This trial is testing a medication called retatrutide to see if it can help improve kidney function. The study focuses on people who are overweight or obese and have chronic kidney disease, with or without Type 2 Diabetes. The goal is to find out if this medication can make their kidneys work better.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

146 Participants Needed

Intensive Glycemic Control for Gestational Diabetes in Overweight/Obese Women

Indianapolis, Indiana
This trial is testing if stricter blood sugar targets can help overweight and obese pregnant women with gestational diabetes have healthier pregnancies. By aiming for lower blood sugar levels, the study hopes to reduce complications for both mothers and babies. The trial will also check if this approach is safe and cost-effective.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 45
Sex:Female

828 Participants Needed

Tirzepatide for Type 1 Diabetes and Obesity

Indianapolis, Indiana
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

905 Participants Needed

Continuous Glucose Monitoring for Diabetes Management in Dementia

Indianapolis, Indiana
Aim 1: Characterize shared decision-making and unmet patient-caregiver dyads needs for patients with diabetes and Alzheimer's Disease and related dementias (ADRD) while using a continuous glucose monitoring (CGM) device. Aim 2: Develop an interactive tool to enhance shared decision-making for diabetes management.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:65+

62 Participants Needed

Del-desiran for Myotonic Dystrophy

Indianapolis, Indiana
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:16 - 65

159 Participants Needed

ZT-01 for Type 1 Diabetes

Indianapolis, Indiana
This trial is testing a drug called ZT-01 to help adults with type 1 diabetes who have low blood sugar at night. ZT-01 increases a hormone that raises blood sugar levels. The study will see if ZT-01 reduces nighttime low blood sugar episodes and check its safety.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

186 Participants Needed

Bionic Pancreas for Cystic Fibrosis

Indianapolis, Indiana
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to use the BP system and the Usual Care group will initiate use of the BP system.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:14+

150 Participants Needed

Long-Term Use of Relacorilant for Cushing Syndrome

Indianapolis, Indiana
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

125 Participants Needed

12345

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Diabetes clinical trials in Evansville, IN pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Diabetes clinical trials in Evansville, IN work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Diabetes trials in Evansville, IN 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Evansville, IN for Diabetes is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Evansville, IN several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Diabetes medical study in Evansville, IN?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Diabetes clinical trials in Evansville, IN?

Most recently, we added Percutaneous Electrical Nerve Field Stimulation for Gastroparesis, Sensing Device for Diabetes and Screening Program for Chronic Kidney Disease in Type 2 Diabetes to the Power online platform.

What is the best treatment for diabetes?

There isn’t one “best” therapy—think of diabetes care as two layers. First, everyone benefits from diabetes education, a balanced diet, regular activity, and routine monitoring. Second, medicines are chosen by diabetes type and other health issues: type 1 always needs insulin (preferably with a continuous glucose monitor or hybrid pump), while type 2 usually starts with metformin plus lifestyle changes and, if more help is needed, adds a GLP-1 or SGLT2 drug (especially when heart, kidney, or weight problems exist) before considering insulin. Work with your healthcare team to revisit these steps every few months so treatment keeps pace with your goals and any new health changes.

How much weight do you need to lose to reverse type 2 diabetes?

Most studies find that you need to shed about 10–15 % of your starting weight—roughly 15 kg (33 lb) for an average-sized adult—to give yourself the best shot at putting type-2 diabetes into remission (normal sugars without diabetes pills). The closer you are to diagnosis and the more weight you keep off—especially if you can pass the 15 kg mark—the higher the odds (up to 80 % in some trials), while smaller losses still improve blood sugar but rarely achieve full remission. Work with your healthcare team to choose a safe approach (intensive diet program, GLP-1 medications, or bariatric surgery) and to monitor that blood-sugar targets stay on track once the weight comes off.

Can diabetics still get Ozempic?

Yes—if you have type-2 diabetes and meet NICE criteria (poor glucose control despite other drugs, or need for weight loss/heart-protection), your GP or diabetes nurse can still prescribe Ozempic; it is not used for type-1 diabetes, pregnancy, or in children. The practical hurdle is the current UK supply shortage, so existing users should order repeats early and stay in touch with their pharmacist, while new patients may need to start a similar medicine (e.g., dulaglutide) until stock returns.

When will oral insulin be available?

No insulin pill has been approved yet. The most advanced candidates (such as insulin tregopil and ORMD-0801) are still redesigning or preparing large Phase 3 studies, and newer “chocolate-capsule” nano-formulations have not even begun human trials until at least 2025. If upcoming studies succeed, regulatory review and manufacturing mean that everyday prescription use is unlikely before the late-2020s at the earliest.

Why is type 2 diabetes not curable?

Type 2 diabetes isn’t considered curable because its root problems—body-wide insulin resistance and gradual loss of insulin-producing β-cells—can return whenever weight or lifestyle slips, and adult β-cells don’t fully regrow once lost. Big, sustained weight loss (through diet, bariatric surgery, or powerful medications) can put the disease into remission for years, but the underlying susceptibility remains, which is why regular follow-up and healthy habits must continue even when blood sugar is normal.

Can I stop taking metformin when my sugar is back to normal?

Normal readings don’t necessarily mean diabetes is cured; for many people the numbers stay normal only because metformin is on board, and stopping it without a plan can let sugars creep back up. Talk with your clinician about whether you truly meet “remission” criteria (HbA1c < 6.5 % for at least 6 months, stable weight, good kidney function); if so, you can try a monitored dose-reduction, check home glucose and repeat labs in 3 months, and restart the drug promptly if levels rise. In short, never quit metformin on your own—make it a shared, step-by-step decision that includes a taper and clear follow-up.

Can a person fully recover from diabetes?

Type 1 diabetes cannot presently be cured; people need lifelong insulin. In type 2 diabetes, some individuals—especially soon after diagnosis—can achieve remission (normal blood-sugar readings without diabetes medicines) through substantial, sustained weight loss or bariatric surgery, but the underlying tendency can return, so regular check-ups remain essential. So while you may control or even “switch off” type 2 diabetes for a time, no form of diabetes is considered permanently gone.

Which country has the cure for diabetes?

No country has an approved, take-home “cure” for diabetes; the Chinese cell-therapy result you may have seen was a one-patient, early-stage experiment that still needs larger trials and regulatory review. Worldwide teams—from China to the United States, Canada, Europe and beyond—are testing stem-cell implants, gene editing and immune therapies, but for now the proven way to stay healthy is tight glucose monitoring, modern medications (e.g., metformin, GLP-1 or insulin) and lifestyle changes, with bariatric surgery offering remission for some people with type 2 diabetes. Stay alert for peer-reviewed trial results and discuss any experimental option with your diabetes specialist before pursuing treatment abroad.

What is the record trial for diabetes?

RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes) was a 5-year study of 4,458 adults with type 2 diabetes that compared adding rosiglitazone to metformin or a sulfonylurea versus the standard metformin-plus-sulfonylurea combination. It showed no overall difference in cardiovascular deaths or hospitalisations (hazard ratio 0.99), but rosiglitazone roughly doubled the risk of heart-failure events and increased bone fractures; these safety concerns, rather than glucose control, ultimately led regulators and doctors to curb use of the drug.

What is the A1C goal for a 70 year old?

For a 70-year-old who already has diabetes, guidelines use a sliding scale: aim below about 7–7.5 % if the person is otherwise healthy and independent, below 8 % if they have multiple illnesses or mild functional decline, and up to 8.5 % if they are frail or in long-term care—these higher limits reduce the risk of dangerous low-blood-sugar episodes. If the 70-year-old is only being screened, the usual cut-offs still apply (normal < 5.7 %, pre-diabetes 5.7-6.4 %, diabetes ≥ 6.5 % confirmed). Work with the healthcare team to choose the target that balances day-to-day safety with long-term benefit.

Popular Searches

By Condition

Depression Clinical Trials in Indiana

Anxiety Clinical Trials in Indiana

Schizophrenia Clinical Trials in Indiana

ADHD Clinical Trials in Indiana

Bipolar Disorder Clinical Trials in Indiana

Multiple Sclerosis Clinical Trials in Indiana

Autism Clinical Trials in Indiana

Treatment Resistant Depression Clinical Trials in Indiana

Borderline Personality Disorder Clinical Trials in Indiana

Social Anxiety Disorder Clinical Trials in Indiana

Parkinson's Disease Clinical Trials in Indiana

Alzheimer's Disease Clinical Trials in Indiana

By Location

Clinical Trials near Indianapolis, IN

Clinical Trials near South Bend, IN

Clinical Trials near Fort Wayne, IN

Clinical Trials near Evansville, IN

Clinical Trials near Elkhart, IN

Clinical Trials near Mishawaka, IN

Clinical Trials near Michigan City, IN

Clinical Trials near Richmond, IN

Clinical Trials near Carmel, IN

Clinical Trials near Lafayette, IN

Clinical Trials near Muncie, IN

Clinical Trials near Munster, IN

Other People Viewed

By Subject

Top Clinical Trials near Evansville, IN

Top Diabetes Clinical Trials

86 Diabetes Trials near Springfield, IL

Top Gestational Diabetes Clinical Trials

Top Diabetes Clinical Trials near Seattle, WA

Top Diabetes Clinical Trials near Miami, FL

Top Diabetes Clinical Trials near Dallas, TX

Top Diabetes Clinical Trials near Tampa, FL

Top Diabetes Clinical Trials near Wilmington, NC

Top Diabetes Clinical Trials near Orlando, FL

Top Diabetes Clinical Trials near Honolulu, HI

Top Pre Diabetes Clinical Trials

By Trial

Continuous Glucose Monitoring for Type 2 Diabetes

Personalized Nutrition Therapy for Type 2 Diabetes

Continuous Glucose Monitoring for Diabetes

Insulin Management Strategies for Diabetes during Pregnancy

Meal Strategies for Type 1 Diabetes

LY3841136 + Tirzepatide for Obesity with Type 2 Diabetes

Diabetes Screening for Early Detection of Pancreatic Cancer · Info for Participants · Clinical Trial 2025 | Power | Power

Group Prenatal Care for Gestational Diabetes

Sedentary Interruptions + Exercise for Reducing Type 2 Diabetes Risk in Children

Mind and Motion for Type 2 Diabetes and Depression · Recruiting Participants for Clinical Trial 2025 | Power | Power

Gene and Vaccine Therapy for Cancer

Healthy Food Vouchers for Type 2 Diabetes

Related Searches

Top Diabetes Clinical Trials near Fort Lauderdale, FL

Top Diabetes Clinical Trials near Fort Worth, TX

Top Diabetes Clinical Trials near Honolulu, HI

Top Diabetes Clinical Trials near Houston, TX

Top Diabetes Clinical Trials near Las Vegas, NV

Top Diabetes Clinical Trials near Los Angeles, CA

Top Diabetes Clinical Trials near Miami, FL

Top Diabetes Clinical Trials near Newport News, VA

Top Diabetes Clinical Trials near New York, NY

Top Diabetes Clinical Trials near Orlando, FL

Top Diabetes Clinical Trials near Plano, TX

Top Diabetes Clinical Trials near Provo, UT

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial